Your browser doesn't support javascript.
loading
A randomized phase II study of SM-88 plus methoxsalen, phenytoin, and sirolimus in patients with metastatic pancreatic cancer treated in the second line and beyond.
Noel, Marcus S; Kim, Semmie; Hartley, Marion L; Wong, Steve; Picozzi, Vincent J; Staszewski, Harry; Kim, Dae Won; Van Tornout, Jan M; Philip, Philip Agop; Chung, Vincent; Ocean, Allyson J; Wang-Gillam, Andrea.
Affiliation
  • Noel MS; Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia, USA.
  • Kim S; TYME Technologies Inc., Bedminster, New Jersey, USA.
  • Hartley ML; The Ruesch Center for the Cure of Gastrointestinal Cancers, Washington, District of Columbia, USA.
  • Wong S; Sarcoma Oncology Research Center, Santa Monica, California, USA.
  • Picozzi VJ; Virginia Mason Hospital and Medical Center, Seattle, Washington, USA.
  • Staszewski H; Mather Hospital, Port Jefferson, New York, USA.
  • Kim DW; The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Van Tornout JM; TYME Technologies Inc., Bedminster, New Jersey, USA.
  • Philip PA; Karmanos Cancer Center, Wayne State University, Michigan, Detroit, USA.
  • Chung V; SWOG, Farmington Hills, Michigan, USA.
  • Ocean AJ; City of Hope, Duarte, California, USA.
  • Wang-Gillam A; Weill Cornell Medicine, New York-Presbyterian Hospital, New York, New York, USA.
Cancer Med ; 11(22): 4169-4181, 2022 11.
Article in En | MEDLINE | ID: mdl-35499204

Full text: 1 Database: MEDLINE Main subject: Pancreatic Neoplasms / Adenocarcinoma Type of study: Clinical_trials Limits: Humans Language: En Journal: Cancer Med Year: 2022 Type: Article Affiliation country: United States

Full text: 1 Database: MEDLINE Main subject: Pancreatic Neoplasms / Adenocarcinoma Type of study: Clinical_trials Limits: Humans Language: En Journal: Cancer Med Year: 2022 Type: Article Affiliation country: United States